Compare PAR & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAR | FLGT |
|---|---|---|
| Founded | 1968 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Medical Specialities |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 699.1M | 579.9M |
| IPO Year | 1995 | 2016 |
| Metric | PAR | FLGT |
|---|---|---|
| Price | $17.43 | $18.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $33.20 | $28.33 |
| AVG Volume (30 Days) | ★ 764.8K | 284.4K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $455,547,000.00 | $18,730,000.00 |
| Revenue This Year | $9.82 | $10.09 |
| Revenue Next Year | $11.27 | $12.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 30.16 | N/A |
| 52 Week Low | $11.59 | $13.46 |
| 52 Week High | $60.42 | $31.04 |
| Indicator | PAR | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 38.82 |
| Support Level | N/A | $17.64 |
| Resistance Level | N/A | $21.56 |
| Average True Range (ATR) | 0.00 | 0.71 |
| MACD | 0.00 | -0.38 |
| Stochastic Oscillator | 0.00 | 29.43 |
PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). Its product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.